Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database

Figures & data

Table 1. Descriptive characteristics of the study population by treatment status (N = 18,058).

Characteristic	Full cohort		Received chemotherapy and/or immunotherapy
	N = 18,058		No (N = 6345)		Yes (N = 11,713)
	n	%	n	%	n	%
Year of diagnosis
2001–2003	4087	22.6	1548	24.4	2539	21.7
2004–2006	4269	23.6	1529	24.1	2740	23.4
2007–2009	4204	23.3	1450	22.9	2754	23.5
2010–2013	5498	30.4	1818	28.9	3680	31.4
Age category
66–70	3374	18.7	793	12.5	2581	22.0
71–75	3997	22.1	1038	16.4	2959	25.3
76–80	4206	23.3	1348	21.3	2858	24.4
81+	6481	35.9	3166	49.9	3315	28.3
Sex
Female	9559	52.9	3345	52.7	6214	523.1
Male	8499	47.1	3000	47.3	5499	46.9
Race (n = 18,030)
Asian	649	3.6	255	4.0	394	3.4
Black	635	3.5	259	4.1	376	3.2
Caucasian	15,846	87.9	5484	86.6	10,362	88.6
Hispanic	410	2.3	172	2.7	238	2.0
Other	490	2.7	166	2.6	324	2.8
Charlson Comorbidity Index
0	7265	40.2	2196	34.6	5291	45.2
1	2813	15.6	904	14.3	1972	16.8
2	3132	17.3	1062	16.7	2000	17.1
3+	4848	26.9	2183	34.4	2450	20.9

Table 2. Top regimens of all treated DLBCL patients at each line of therapy by treatment initiation year.

Treatment regimen	All treated		Treatment initiation year
			2001–2003		2004–2006		2007–2009		2010 – 2014
	n	%	n	%	n	%	n	%	n	%
First line of therapy (N = 11,713)
R-CHOP-based	7501	64.0	1214	50.5	1736	64.3	1906	69.0	2645	68.8
CHOP-based	569	4.9	418	17.4	73	2.7	48	1.7	30	0.8
Rituximab only	909	7.8	203	8.5	259	9.6	184	6.7	263	6.8
Rituximab + other	2091	17.9	369	15.4	553	20.5	499	18.1	670	17.3
Other	643	5.5	199	8.3	81	3.0	127	4.6	236	6.1
Second line of therapy (N = 2745)
R-CHOP-based	590	21.5	125	18.3	136	19.1	140	21.5	189	27.1
CHOP-based	47	1.7	24	3.5	11	1.5	*	*	*	*
Rituximab only	101	3.7	69	10.1	15	2.1	*	*	*	*
Rituximab + other	945	34.4	192	28.1	229	32.1	237	36.4	287	41.2
Other	1062	38.7	273	40.0	322	45.2	261	40.0	206	29.6
Third line of therapy (N = 382)
R-CHOP-based	60	15.4	20	14.9	*	*	*	*	23	29.9
CHOP-based	*	*	*	*	*	*	*	*	*	*
Rituximab only	51	13.1	23	17.2	12	11.9	*	*	*	*
Rituximab + other	181	46.4	47	35.1	50	49.5	50	64.1	34	44.2
Other	**	**	**	**	27	26.7	**	**	**	**

*Cell count of <11 patients. Numbers not displayed for patient confidentiality.**Numbers omitted to protect patient confidentiality.

Table 3. Top regimens of all treated DLBCL patients at each line of therapy by age group at diagnosis.

Treatment regimen	Age group at diagnosis, years
	66–70		71–75		76–80		>80
	n	%	n	%	n	%	n	%
First line of therapy
R-CHOP-based	1941	75.2	2150	72.7	1870	65.4	1540	46.5
CHOP-based	135	5.2	121	4.1	158	5.5	119	3.6
Rituximab only	89	3.5	119	4.0	172	6.0	529	16.0
Rituximab + other	272	10.5	412	13.9	522	18.3	885	26.7
Other	144	5.6	121	4.1	136	4.8	242	7.3
Second line of therapy
R-CHOP-based	130	19.8	175	23.4	154	22.8	131	19.7
CHOP-based	*	*	21	2.8	*	*	11	1.7
Rituximab only	18	2.7	23	3.1	28	4.2	32	4.8
Rituximab + other	231	35.2	248	33.2	220	32.6	246	37.0
Other	**	**	281	37.6	**	**	245	36.8
Third line of therapy
R-CHOP-based	12	13.8	20	17.9	14	15.4	14	14.0
CHOP-based	*	*	*	*	*	*	0	0.0
Rituximab only	*	*	*	*	16	17.6	16	16.0
Rituximab + other	44	50.6	52	46.4	39	42.9	46	46.0
Other	**	**	28	25.0	**	**	24	24.0

*Cell count of <11 patients. Numbers not displayed for patient confidentiality.

**Numbers omitted to protect patient confidentiality.

Table 4. First line of therapy by treatment initiation year for patients aged ≥81 years.

Treatment regimen	Treatment initiation year
	2001–2003		2004–2006		2007–2009		2010–2014
	n	%	n	%	n	%	n	%
First line of therapy
R-CHOP-based	211	33.5	377	47.3	379	48.9	573	51.5
CHOP-based	83	13.2	18	2.3	11	1.4	*	*
Rituximab only	124	19.7	152	19.1	113	14.6	140	12.6
Rituximab + other	132	21.0	224	28.1	219	28.3	310	27.9
Other	80	12.7	26	3.3	53	6.8	83	7.5

*Cell count of <11 patients. Numbers not displayed for patient confidentiality.

Figure 1. Overall survival of DLBCL patients by year of diagnosis.

Figure 2. Overall survival of DLBCL patients by age group at diagnosis.

Figure 3. Overall survival of DLBCL patients by CCI (Charlson Comorbidity Index Group).

Table 5. Estimated probability of survival over time by year of DLBCL diagnosis (estimate [95% confidence interval]).

		Year of DLBCL diagnosis
Time	Overall	2001–2003	2004–2006	2007–2009	2010–2013
6 months	0.683 (0.676, 0.690)	0.663 (0.649, 0.678)	0.668 (0.654, 0.682)	0.684 (0.670, 0.698)	0.708 (0.696, 0.720)
1 year	0.579 (0.572, 0.586)	0.544 (0.529, 0.559)	0.553 (0.539, 0.568)	0.583 (0.569, 0.598)	0.621 (0.608, 0.634)
18 months	0.522 (0.515, 0.529)	0.482 (0.467, 0.498)	0.498 (0.483, 0.513)	0.524 (0.509, 0.539)	0.569 (0.556, 0.582)
2 years	0.485 (0.477, 0.492)	0.446 (0.431, 0.461)	0.463 (0.449, 0.478)	0.489 (0.474, 0.504)	0.527 (0.514, 0.541)
3 years	0.433 (0.425, 0.440)	0.393 (0.378, 0.408)	0.414 (0.400, 0.429)	0.437 (0.422, 0.452)	0.474 (0.460, 0.489)
5 years	0.356 (0.348, 0.363)	0.318 (0.304, 0.332)	0.344 (0.330, 0.358)	0.362 (0.348, 0.377)	0.389 (0.367, 0.412)